Listed

DENTSPLY SIRONA Inc.: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 2, 2023 and accepted by EDGAR at Nov 2, 2023, 16:52 ET.

Share

Management's discussion and analysis

As filed, 61,629 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Information included in or incorporated by reference in this Form 10-Q, and other filings with the SEC and the Company’s press releases or other public statements, contains or may contain forward-looking statements. Please refer to the discussion under the header “Forward-Looking Statements and Associated Risks” in the forepart of this Form 10-Q.

Company Profile

DENTSPLY SIRONA Inc. is the world's largest manufacturer of professional dental products and technologies, with a 136-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental equipment, dental consumable, and orthodontic and implant products under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. Dentsply Sirona’s products provide innovative, high-quality, and effective solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona’s worldwide headquarters is located in Charlotte, North Carolina. The Company’s shares of common stock are listed in the United States on the Nasdaq stock market under the symbol XRAY.

Material Weaknesses in Internal Control Over Financial Reporting

As previously disclosed, management determined there were material weaknesses in the Company’s internal control over financial reporting as of December 31, 2022, which have not been remediated as of September 30, 2023. For more information about the identified material weaknesses in internal control over financial reporting and the Company’s remedial actions, please see Part I, Item 4 Controls and Procedures of this Form 10-Q.

BUSINESS

Effective April 1, 2023, and in conjunction with our updated strategic operating realignment, the Company's reporting segment structure changed from Technology & Equipment and Consumables to (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare.

A description of the products and services provided within each of the Company’s four reportable segments is provided below. Refer also to Note 6, Segment Information, in Part I, Item 1 of this Form 10-Q for more information.

Connected Technology Solutions

This segment is responsible for the design, manufacture, and sales of the Company’s dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories.

Essential Dental Solutions

This segment is responsible for the design, manufacture, and sales of the Company’s value-added endodontic, restorative, and preventive consumables products and small equipment used in dental offices for the treatment of patients. Offerings in this segment also include specialized treatment products used in the preparation of dental appliances..

Orthodontic and Implant Solutions

This segment is responsible for the design, manufacture, and sales of the Company’s various digital implant systems and innovative dental implant products, digital dentures and dentist directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by our cloud-based platform.

Wellspect Healthcare

This segment is responsible for the design, manufacture, and sales of the Company’s innovative continence care solutions.

The impact of the recent Israel-Hamas war

The recent terrorist attacks by Hamas militants crossing the border from Gaza to Israel in October 2023 and the subsequent military response by the Israeli government has resulted in significant unrest and uncertainty within that region, including the possibility that escalating violence and involvement of other terrorist groups from neighboring countries may further impact our employees and operations.

The Company’s operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one in southern Israel, which employ approximately 300 associates. These facilities remain open and continue to operate. We may, however, determine to discontinue production for the safety of our employees, or we could face future production slowdowns or interruptions at either location due to the impacts of the war including personnel absences as a number of our employees have been called to active military duty, or due to other resource constraints such as the inability to source materials for production.

For the quarter ended September 30, 2023, net sales of products produced at these sites comprise approximately 3% of our consolidated net sales and 18% of the net sales attributed to our Orthodontics and Implants Solutions segment. Net assets within Israel total $193 million as of September 30, 2023, consisting primarily of acquired technology, cash, inventory, and property, plant and equipment associated our operations in country. While the conflict had no impact on results for the quarter ended September 30, 2023, the Company has initiatives underway to move inventory to locations in southern Europe to limit the disruption to our implants product sales and operations for the fourth quarter of 2023 and fiscal year 2024.

Additionally, the Company sells products from across our business portfolio to distributors of dental products and direct to dental practices within Israel and its neighboring countries which may face reduced patient traffic and demand for our products in the near term. Net sales for products sold to our customers in Israel comprise less than 1% of our consolidated net sales for the quarter ended September 30, 2023.

While Israel does not constitute a material portion of our business, a significant escalation or expansion of the conflict's current scope and economic disruption could result in loss of sales and market position, disrupt our supply chain, broaden inflationary costs including energy prices, and have a material adverse effect on our results of operations, including impairment of the net assets in Israel or the goodwill associated our Implants & Prosthetics reporting unit.

The impact of the war in Ukraine

In February 2022, as a result of the invasion of Ukraine by Russia, economic sanctions were imposed by the United States, the European Union, and certain other countries on Russian financial institutions and businesses. Due to the medical nature of our products, the current sanctions have not materially restricted the Company's ability to continue selling many of our products to customers located in Russia. The Company also sources certain raw materials and components from Russia and Ukraine, and to minimize the adverse impacts from disrupted supply chains related to these items, the Company has purchased sufficient quantities for the near term, and is in the process of identifying alternative sources for the longer term. The Company’s operations in Ukraine consist primarily of R&D activities, which continue uninterrupted from other locations in order to focus on the safety of employees. Overall, the Company's operations in Russia and Ukraine have not been materially impacted by the conflict, and consequently, the Company has not recorded any allowance for doubtful accounts, inventory reserves, or asset impairments through the quarter ended September 30, 2023 as a result of these developments.

For the quarter ended September 30, 2023, net sales in Russia and Ukraine were approximately 2% of our consolidated net sales, and net assets in these countries were $57 million. These net assets include $34 million of cash and cash equivalents held within Russia as of September 30, 2023. Due to currency control measures imposed by the Russian government which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we may be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs, if at all.

While neither Russia nor Ukraine constitutes a material portion of our business, a significant escalation or expansion of economic disruption or the conflict's current scope could result in a loss of sales, disrupt our supply chain, broaden inflationary costs, and have a material adverse effect on our results of operations.

The impact of global economic conditions

Markets in several regions, particularly in Europe, have experienced varying degrees of recessionary pressures and face continued concerns about the systemic impacts of adverse economic conditions and geopolitical issues. In addition, changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, and the conflict in Ukraine have all contributed to a period of higher inflation across the industry and the regions in which the Company operates.

As a result, the Company has experienced higher prices for certain raw materials, particularly for electronic components which have in some cases required incremental procurement costs such as brokers' fees during the year, and consequently a negative impact to margins. The Company has also experienced delays in converting our backlog due to continued supply chain disruptions, which has negatively impacted both revenues and margins. Although the Company has experienced recent improvement in its supply chain, we expect a continuation of these trends including disruptions and inflationary pressure on the cost of both raw material and wages, the effect of which will depend on the Company’s ability to successfully mitigate and offset the related impacts.

The deterioration in macroeconomic conditions has also negatively affected demand for the Company's products and may continue to do so into the future. Specifically, the increase in interest rates in the last twelve months has put pressure on the ability and willingness of our customers to obtain financing for equipment purchases which affects volumes for these products. Additionally, the recessionary environment in general particularly for certain regions such as southern Europe has depressed demand for elective procedures including sales of implants and aligner solutions.

In anticipation of a continued inflationary trend and potentially deteriorating macroeconomic environment, the Company has attempted to mitigate these pressures through the following actions, among others:

  • Driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation;
  • Implementing cost-containment measures, as well as intensifying continuous improvement and restructuring programs, in our manufacturing and distribution facilities and other areas of our business; and
  • Optimizing our customer management and implementing strategic investments in our commercial sales organization in key markets, particularly the United States.

As explained further in the Results of Operations section below, the Company has partially offset these elevated costs in certain areas of the business with price increases during the year. Should the higher inflationary environment continue, the Company may be unable to raise the prices of our products and services sufficiently to keep up with the rate of inflation which could have a material adverse effect on our results of operations and financial condition.

RESULTS OF OPERATIONS, THREE MONTHS ENDED SEPTEMBER 30, 2023 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2022

Net Sales

The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also presents the changes in net sales on an organic sales basis, which is a Non-GAAP measure. The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired and divested businesses recorded prior to the first anniversary of the acquisition or divestiture; (2) net sales attributable to discontinued product lines in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period’s currency exchange rates.

Our measure of organic sales may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Organic sales is an important internal measure for the Company, and its senior management receives a monthly analysis of operating results that includes organic sales. The performance of the Company is measured on this metric along with other performance metrics.

The Company discloses changes in organic sales to allow investors to evaluate the performance of the Company’s operations exclusive of the items listed above that may impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this supplemental information is helpful in understanding underlying net sales trends.

The Company's net sales for the three months ended September 30, 2023 and 2022, and a reconciliation to the percentage change in organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $947 $947 $— —%
Foreign exchange impact 0.3%
Organic sales (0.3%)

Percentages are based on actual values and may not reconcile due to rounding.

The slight decrease in organic sales was primarily due to weaker overall demand, particularly in Europe and for our Connected Technology products as described below, mostly offset by price increases and strong demand in the Rest of World region.

Net Sales by Segment

Connected Technology Solutions

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $276 $286 $(10) (3.8%)
Foreign exchange impact 0.8%
Organic sales (4.6%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to lower volumes of imaging equipment, particularly in Europe, partially offset by increased volumes of CAD/CAM equipment in the United States and price increases.

Essential Dental Solutions

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $347 $348 $(1) (0.3%)
Foreign exchange impact 0.6%
Organic sales (0.9%)

Percentages are based on actual values and may not reconcile due to rounding.

The slight decrease in organic sales was primarily driven by weaker overall demand particularly in Europe, partially offset by price increases and stronger demand in Rest of World.

Orthodontic and Implant Solutions

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $252 $247 $5 2.2%
Foreign exchange impact (1.5%)
Organic sales 3.7%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by higher sales volumes of orthodontic aligners for both our in-office and direct-to-consumer aligner solutions, in the United States and Europe, and stronger demand for implants products in Rest of World. These increases were partially offset by lower volumes for implants and prosthetics products in the United States and Europe.

Wellspect Healthcare

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $72 $66 $6 9.9%
Foreign exchange impact 3.1%
Organic sales 6.8%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was the result of a favorable mix of product sales across all regions, particularly in Europe, price increases, and favorable impact of new product launches, partially offset by a reduction in overall volumes.

Net Sales by Region

United States

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $356 $357 $(1) (0.2%)
Foreign exchange impact 0.7%
Organic sales (0.9%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily driven by lower volumes of consumables products, imaging products and implants products, partially offset by price increases and higher volumes of orthodontic aligners. Sales were also positively affected by higher wholesale volumes for CAD/CAM products relative to the third quarter of the prior year due in part to timing of sales to distributors. Volumes for CAD/CAM products in the third quarter of 2023 included a seasonal build in distributor inventory of approximately $20 million, compared to a smaller build in distributor inventory of approximately $7 million during the same quarter of 2022. Despite this higher year over year seasonal build, distributor inventory levels for CAD/CAM products remained low as of the end of the third quarter 2023 relative to historical averages.

Europe

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $354 $358 $(4) (1.1%)
Foreign exchange impact 1.7%
Organic sales (2.8%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to overall lower volumes for treatment centers and imaging products as well as endodontic and restorative consumables as a result of less favorable market and macroeconomic trends, particularly in Germany. These decreases were partially offset by price increases as well as increased volumes for healthcare and orthodontic products.

Rest of World

Net sales for the three months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Net sales $237 $232 $5 2.0%
Foreign exchange impact (2.5%)
Organic sales 4.5%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by improving demand for both consumables products and implants products. In the third quarter of 2023, the local volume-based procurement program in China continued to result in increased volumes for implants products, partially offset by price reductions, representing a marked improvement from the program's adverse impact earlier in 2023. These increases were partially offset by declines in volumes for Connected Technology Solutions products.

Gross Profit

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Gross profit $495 $508 $(13) (2.7%)
Gross profit as a percentage of net sales 52.2% 53.7% (150) bps

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit for the quarter declined due to lower sales volumes described above, partially offset by the benefit of favorable product mix, price increases, lower distribution costs and favorable foreign currency translation. Gross profit as a percentage of net sales further declined due to inflation of material costs, higher warranty costs, and increased inventory obsolescence including product rationalization charges.

Operating Expenses

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change % Change
Selling, general, and administrative expenses ("SG&A") $372 $401 $(29) (7.6%)
Research and development expenses ("R&D") 46 41 5 12.2%
Goodwill and intangible asset impairments 307 1,281 (974) NM
Restructuring and other costs 6 3 3 149.5%
SG&A as a percentage of net sales 39.1% 42.4% (330) bps
R&D as a percentage of net sales 4.8% 4.3% 50 bps

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

SG&A Expenses

SG&A expenses as a percentage of net sales decreased due to savings from the Company's recently enacted restructuring plan, a gain from release of employee compensation accruals as a result of a settlement, a reduction in professional service costs, and lower advertising including trade show costs. These decreases were partially offset by increased headcount costs primarily from incremental investments in the Company's customer-facing roles, merit increases as compared to the prior year, and unfavorable impact from foreign exchange on operating expenses.

R&D Expenses

R&D expenses increased from the third quarter of 2022 as the Company continues to prioritize ongoing investments in digital workflow solutions, product development initiatives, software development including clinical application suite and cloud deployment. The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

Goodwill and Intangible Asset Impairments

Goodwill and intangible asset impairments decreased from the third quarter of 2022 due to a lower level of impairment charges. For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Restructuring and Other Costs

During the three months ended September 30, 2023, the Company recorded net expense of $6 million of restructuring and other costs which consist primarily of charges in conjunction with the restructuring plan announced in February 2023. For further details refer to Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Segment Adjusted Operating Income

(in millions, except percentages)(a) Three Months Ended September 30, 2023 2022 $ Change % Change
Connected Technology Solutions $22 $25 $(3) (12.0%)
Essential Dental Solutions 115 110 5 4.5%
Orthodontic and Implant Solutions 31 40 (9) (22.5%)
Wellspect Healthcare 26 19 7 36.8%

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

Connected Technology Solutions

The decrease in segment adjusted operating income is due to lower organic sales noted above, increased warranty costs and an increase in SG&A headcount expenses due to reinvestment of some cost savings from reductions in headcount to fill key customer-facing roles. These decreases were partially offset by a reduction in professional services costs and favorable impact from foreign currency exchange.

Essential Dental Solutions

The increase in segment adjusted operating income is due improved margins, favorable impact of product mix, reduction in professional services, and a favorable impact from foreign currency exchange. This was partially offset by the organic sales decrease noted above, increased inventory obsolescence including product rationalization charges, and an increase in SG&A headcount expenses due to reinvestment of some cost savings from reductions in headcount to fill key customer-facing roles.

Orthodontic and Implant Solutions

The decrease in segment adjusted operating income is due to inflation of material costs, an unfavorable impact from foreign currency exchange, higher inventory obsolescence expense during the period, and an increase in SG&A headcount expenses due to reinvestment of some cost savings from reductions in headcount to primarily fill key customer-facing roles. This was partially offset by the organic sales increase for orthodontics products noted above.

Wellspect Healthcare

The increase in segment operating income results from the increase in sales noted above, as well as margin improvement due to the favorable manufacturing impact of higher volumes.

Other Income and Expense

(in millions)

Three Months Ended September 30, 2023 2022 $ Change % Change
Interest expense, net $18 $14 $4 24.5%
Other (income) expense, net (4) 9 (13) NM
Net interest and other expense (income) $14 $23 $(9)

NM - Not meaningful

Interest expense, net

Interest expense, net for the three months ended September 30, 2023 increased compared to the three months ended September 30, 2022, driven primarily by higher interest rates on short-term and other borrowings.

Other (income) expense, net

Other (income) expense, net for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 is as follows:

(in millions)

Three Months Ended September 30, 2023 2022 $ Change
Foreign exchange (gains) losses $(5) $3 $(8)
Loss from equity method investments 1 4 (3)
Defined benefit pension plan expenses 1 2 (1)
Other non-operating income (1) — (1)
Other (income) expense, net $(4) $9 $(13)

Foreign exchange losses (gains) are primarily related to the revaluation of intercompany payables and loans, as well as a benefit in the three months ended September 30, 2023 from the Swiss franc foreign exchange forward contracts described in Note 9, Financial Instruments and Derivatives, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Income Taxes and Net Income

(in millions, except percentages)

Three Months Ended September 30, 2023 2022 $ Change
Provision (benefit) for income taxes $16 $(164) $180
Effective income tax rate (6.3%) 13.2%
Net loss attributable to Dentsply Sirona $(266) $(1,077) $811
Net loss per common share - diluted $(1.25) $(5.01)

Percentages are based on actual values and may not reconcile due to rounding.

Provision for income taxes

For the three months ended September 30, 2023, the income tax expense was $16 million as compared to the income tax benefit of $164 million during the three months ended September 30, 2022. The tax benefit in 2022 was driven by the tax- deductible goodwill and intangible impairment.

RESULTS OF OPERATIONS, NINE MONTHS ENDED SEPTEMBER 30, 2023 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2022

Net Sales

The Company's net sales for the nine months ended September 30, 2023 and 2022, and the reconciliation to organic sales are as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $2,953 $2,939 $14 0.5%
Foreign exchange impact (1.9%)
Organic sales 2.4%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was led by performance in the Essential Dental Solutions and Orthodontic and Implant Solutions segments, primarily driven by price increases within both segments and higher volumes for orthodontic aligners. The increases were partially offset by lower volumes for implants and Connected Technology Solution products.

Net Sales by Segment

Connected Technology Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $850 $875 $(25) (2.9%)
Foreign exchange impact (2.3%)
Organic sales (0.6%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to lower volumes, particularly in Europe, partially offset by price increases and strengthening sales of new treatment centers and CAD/CAM products. Sales of CAD/CAM products in the United States were also positively impacted by the timing of sales to distributors relative to the first nine months of 2022 as explained below.

Essential Dental Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $1,110 $1,084 $26 2.3%
Foreign exchange impact (1.4%)
Organic sales 3.7%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was due to price increases, as well as higher volumes of preventive and restorative products, particularly in the United States. These increases were partially offset by lower volumes of endodontic consumables.

Orthodontic and Implant Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $781 $772 $9 1.3%
Foreign exchange impact (2.1%)
Organic sales 3.4%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by higher volumes of orthodontic aligners, particularly in the United States, coupled with an increase in volumes for implants and prosthetics products in Rest of World. This was partially offset by lower volumes of implants and prosthetics products in the other regions.

Wellspect Healthcare

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $212 $208 $4 2.3%
Foreign exchange impact (2.2%)
Organic sales 4.5%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was the result of a favorable mix of product sales across all regions, particularly in Europe, and price increases.

Net Sales by Region

United States

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $1,069 $1,023 $46 4.5%
Foreign exchange impact —%
Organic sales 4.5%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was driven primarily by price increases and higher demand for consumables and orthodontics aligners. This was partially offset by lower volumes for imaging and implants products. Sales were also positively affected by wholesale volumes for CAD/CAM products relative to the first nine months of 2022 due in part to timing of sales to distributors. Volumes for CAD/CAM products in the first nine months of 2023 included a seasonal build in distributor inventory of approximately $6 million compared to a reduction in distributor inventory of approximately $32 million during the first nine months of 2022. Distributor inventory levels for CAD/CAM products remained low as of the end of the third quarter relative to historical averages.

Europe

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $1,153 $1,183 $(30) (2.5%)
Foreign exchange impact (1.3%)
Organic sales (1.2%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily driven by overall lower volumes for Connected Technology Solutions and Implants & Prosthetics Solutions products as a result of unfavorable market and macroeconomic trends, partially offset by price increases and higher volumes of orthodontic aligners.

Rest of World

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Net sales $731 $733 $(2) (0.3%)
Foreign exchange impact (5.5%)
Organic sales 5.2%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by price increases and improved demand for Essential Dental Solutions products, as well as certain Connected Technology Solutions products, including treatment centers.

Gross Profit

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Gross profit $1,564 $1,610 $(46) (2.9%)
Gross profit as a percentage of net sales 53.0% 54.8% (180) bps

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit declined due to foreign currency translation headwinds of $26 million, higher warranty costs, increased inventory obsolescence including product rationalization charges, and higher material costs. These factors were partially offset by sales increases noted above, favorable sales mix driven by higher demand for higher margin consumables products, and improvements in the profitability of orthodontics products.

Operating Expenses

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Selling, general, and administrative expenses ("SG&A") $1,204 $1,187 $17 1.4%
Research and development expenses 141 131 10 7.0%
Goodwill and intangible asset impairments 307 1,281 (974) NM
Restructuring and other costs 70 13 57 NM
SG&A as a percentage of net sales 40.8% 40.4% 40 bps
R&D as a percentage of net sales 4.8% 4.5% 30 bps

Percentages are based on actual values and may not reconcile due to rounding.

SG&A Expenses

SG&A expenses as a percentage of net sales increased in part due to professional service costs related to the restructuring and transformation initiatives, and an increase in travel as more customer-related interactions have returned to in-person format following the recovery from COVID-19. Headcount costs increased, primarily as a result of incremental investments in the Company's customer-facing roles, incentive compensation and merit increases. These increases were partially offset by a benefit from lower than expected severance costs due to a settlement, and lower advertising costs.

R&D Expenses

R&D expenses increased compared to the first nine months of 2022. The Company continues to prioritize ongoing investments in digital workflow solutions, product development initiatives, software development including clinical application suite and cloud deployment. The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

Goodwill and Intangible Asset Impairments

Goodwill and intangible asset impairments decreased compared to the nine months ended September 30, 2022, due to a lower level of impairment charges. For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Restructuring and Other Costs

During the nine months ended September 30, 2023, the Company recorded net expense of $70 million of Restructuring and other costs which consist primarily of charges associated with the restructuring plan announced in February 2023. For further details, see Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Segment Adjusted Operating Income

(in millions, except percentages)(a) Nine Months Ended September 30, 2023 2022 $ Change % Change
Connected Technology Solutions $54 $101 $(47) (46.5%)
Essential Dental Solutions 365 361 4 1.1%
Orthodontic and Implant Solutions 129 157 (28) (17.8%)
Wellspect Healthcare 65 57 8 14.0%

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

Connected Technology Solutions

The decrease in segment adjusted operating income is due to an increase in SG&A costs including increased headcount primarily for key customer-facing roles, unfavorable impact from product mix, inflation of material costs, increased warranty costs, and an increase in inventory obsolescence expense, partially offset by the organic sales increase noted above.

Essential Dental Solutions

The increase in segment adjusted operating income is due to the organic sales increase noted above partially offset by an increase in SG&A costs including headcount increase for customer-facing roles and trade event related expenses, inflation of material costs, and an unfavorable impact from product mix.

Orthodontic and Implant Solutions

The decrease in segment adjusted operating income is due to the unfavorable impact of foreign currency exchange, inflation of material costs, and an increase in SG&A costs including increased headcount primarily for key customer-facing roles, and sales event related expenses partially offset by the organic sales increase and improved profitability for orthodontics products noted above.

Wellspect Healthcare

The increase in segment adjusted operating income resulted from the increase in organic sales noted above, as well as margin improvement due to the favorable manufacturing impact of higher volumes.

Other Income and Expense

(in millions, except percentages)

Nine Months Ended September 30, 2023 2022 $ Change % Change
Interest expense, net $58 $41 $17 40.3%
Other (income) expense, net 16 20 (4) NM
Net interest and other expense $74 $61 $13

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

Interest expense, net

Interest expense, net for the nine months ended September 30, 2023 increased by $17 million compared to the nine months ended September 30, 2022, driven primarily by higher interest rates on short-term and other borrowings.

Other (income) expense, net

Other (income) expense, net for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was as follows:

(in millions)

Nine Months Ended September 30, 2023 2022 $ Change
Foreign exchange losses (gains) $7 $(1) $8
Loss from equity method investments 4 14 (10)
Defined benefit pension plan expenses 5 6 (1)
Other non-operating loss — 1 (1)
Other (income) expense, net $16 $20 $(4)

Foreign exchange losses (gains) are primarily related to the revaluation of intercompany payables and loans, as well as a benefit in the first nine months of 2023 from the Swiss franc foreign exchange forward contracts described in Note 9, Financial Instruments and Derivatives, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Income Taxes and Net Income

(in millions, except per share amounts and percentages)

Nine Months Ended September 30, 2023 2022 $ Change
Benefit for income taxes $(28) $(128) $100
Effective income tax rate 12.1% 12.1%
Net loss attributable to Dentsply Sirona $(199) $(935) $736
Net loss per common share - diluted $(0.94) $(4.34)

Percentages are based on actual values and may not reconcile due to rounding.

Provision for income taxes

For the nine months ended September 30, 2023, the income tax benefit was $28 million as compared to the tax benefit of $128 million during the nine months ended September 30, 2022. The tax benefit in the current period was driven by the partial valuation allowance release of net operating loss carryforwards due to the Company’s ability to project future taxable income as a result of internal debt restructurings. The tax benefit in 2022 was driven by the tax-deductible goodwill and intangible impairment.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Goodwill Impairment

Goodwill represents the excess cost over the fair value of the identifiable net assets of businesses acquired. Goodwill is not amortized; instead, it is tested for impairment annually or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired, or if a decision is made to sell a business. Judgment is involved in determining if an indicator of impairment has occurred during the course of the year. Such indicators may include a decline in expected cash flows, unanticipated competition or slower growth rates, among others. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is "more likely than not" that the fair value of a reporting unit is less than its carrying amount including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. It is important to note that fair values which could be realized in an actual transaction may differ from those used to evaluate the impairment of goodwill.

Goodwill is allocated among reporting units and evaluated for impairment at that level. The Company's reporting units are either an operating segment or one level below its operating segments, as determined in accordance with ASC 350.

Indefinite-Lived Intangible Asset Impairment

Indefinite-lived intangible assets consist of tradenames, trademarks and in process R&D and are not subject to amortization; instead, they are tested for impairment annually or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired or if a decision is made to sell a business.

The fair value of acquired tradenames and trademarks is estimated by the use of a relief from royalty method, which values an indefinite-lived intangible asset by estimating the royalties saved through the ownership of an asset. Under this method, an owner of an indefinite-lived intangible asset determines the arm’s length royalty that likely would have been charged if the owner had to license the asset from a third party. The royalty rate, which is based on the estimated rate applied against forecasted sales, is tax-effected and discounted at present value using a discount rate commensurate with the relative risk of achieving the cash flow attributable to the asset. Management judgment is necessary to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. Other assumptions are consistent with those applied to goodwill impairment testing. Alternatively, the Company may assess indefinite-lived intangible assets qualitatively.

The determination of fair value involves uncertainties around the forecasted cash flows as it requires management to make assumptions and apply judgment to estimate future business expectations. Those future expectations include, but are not limited to, macroeconomic factors such as higher cost of capital, cost inflation, unfavorable foreign currency impacts, and increased supply chain costs and new product development changes for these reporting units.

Any deviation in actual financial results compared to the forecasted financial results or valuation assumptions used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings.

Goodwill and Indefinite-Lived Intangible Asset Impairment Results

The Company previously assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2023. Based on that annual impairment test, which computed fair values of reporting units using a discounted cash flow model with inputs developed using both internal and market-based data, it was determined that the fair values of its reporting units and indefinite-lived intangible assets more likely than not exceeded their carrying values, resulting in no impairment.

In the quarter ended September 30, 2023, the Company identified indicators of a "more likely than not" impairment related to its Connected Technology Solutions reporting unit, which comprises all of the Connected Technology Solutions segment. The decline in fair value for this reporting unit was driven by adverse macroeconomic factors as a result of weakened demand particularly in European markets and increased discount rates. Since the second quarter, core underlying market interest rates, which serve as the basis for the discount rate assumptions in our impairment models, rose by approximately 110 basis points. These factors are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term, particularly for demand for products which are commonly financed by end customers which are adversely impacted by an environment of higher interest rates. As a result, the Company recorded a pre-tax goodwill impairment charge as of September 30, 2023 related to the Connected Technology Solutions reporting unit of $291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment.

Additionally, in conjunction with the goodwill impairment test in the quarter ended September 30, 2023, the Company tested the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment for impairment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment, and determined certain tradenames and trademarks were impaired. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $14 million and $2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023. The impairment charge was primarily driven by macroeconomic factors such as weakened demand, higher cost of capital, and cost inflation, which are contributing to reduced forecasted revenues. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2023, any further decline in key assumptions could result in additional impairment in future periods.

Refer to Part I, Item 1, Note 13, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q for further discussion of the Company's annual and interim goodwill and indefinite-lived intangible asset impairment testing.

LIQUIDITY AND CAPITAL RESOURCES

(in millions)

Cash (used in) provided by: Nine Months Ended September 30, 2023 2022 $ Change
Operating activities $217 $375 $(158)
Investing activities (69) (109) 40
Financing activities (179) (168) (11)
Effect of exchange rate changes on cash and cash equivalents (25) (19) (6)
Net (decrease) increase in cash and cash equivalents $(56) $79 $(135)

Cash provided by operating activities decreased compared to the nine months ended September 30, 2022, primarily as a result of changes in working capital including lower collections from sales during the current period, higher operating expenses, and timing of payments to vendors. These decreases in operating cash were offset by other changes in working capital including a lower build of inventory during the current period. At September 30, 2023, the number of days for sales outstanding in accounts receivable increased by 6 days to 61 days as compared to 55 days at December 31, 2022, and the number of days of sales in inventory increased by 1 days to 138 days at September 30, 2023 as compared to 137 days at December 31, 2022.

The decrease in cash used in investing activities was primarily due to higher cash received on derivatives of $29 million and lower capital expenditures of $8 million. The Company estimates capital expenditures to be in the range of approximately $140 million to $160 million for the full year 2023 and expects these investments to include expansion of facilities to provide incremental space for growth and the consolidation of operations for enhanced efficiencies, as well as capital investment related to modernizing our integrated financial systems and enterprise resource planning across the business.

The increase of cash used in financing activities compared to the nine months ended September 30, 2022 was primarily driven by higher dividends paid of $8 million, lower proceeds from the exercise of stock options of $6 million and higher short-term borrowings of $4 million. The Company's total borrowings increased by a net $46 million during the nine months ended September 30, 2023, mainly due to the use of the Company's commercial paper program, offset by a decrease of $17 million due to exchange rate fluctuations on debt denominated in foreign currencies.

During the nine months ended September 30, 2023, the Company entered into an accelerated share repurchase agreement ("ASR Agreement") of $150 million with approximately 3.1 million shares delivered during March 2023 at a volume-weighted average price of $38.74 representing $120 million of the total anticipated repurchase. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement resulting in a total 3.9 million shares repurchased under the agreement. At September 30, 2023, $590 million of authorization remained available for future share repurchases. Additional share repurchases, if any, may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. At September 30, 2023, the Company held 52.7 million shares of treasury stock.

The Company's ratio of total net debt to total capitalization was as follows:

(in millions, except percentages)

September 30, 2023 December 31, 2022
Current portion of debt $187 $118
Long-term debt 1,803 1,826
Less: Cash and cash equivalents 309 365
Net debt $1,681 $1,579
Total equity 3,371 3,812
Total capitalization $5,052 $5,391
Total net debt to total capitalization ratio 33.3% 29.3%

At September 30, 2023, the Company had a total remaining borrowing capacity of $562 million under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company's borrowing capacity includes a $700 million credit facility available through May 2028. The Company also has available an aggregate $500 million under a U.S. dollar commercial paper facility. The $700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is $700 million. The Company had $165 million outstanding borrowings under the commercial paper facility at September 30, 2023 resulting in $535 million remaining available under the revolving credit and commercial paper facilities. The Company also has access to $48 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At September 30, 2023, the Company had $21 million outstanding under short-term borrowing arrangements.

The Company’s revolving credit facility, term loans and senior notes contain certain covenants relating to the Company's operations and financial condition. The most restrictive of these covenants are: a ratio of total debt outstanding to total capital not to exceed 0.6, and a ratio of operating income excluding depreciation and amortization to interest expense of not less than 3.0 times, in each case, as such terms are defined in the relevant agreement. Any breach of any such covenants would result in a default under the existing debt agreements that would permit the lenders to declare all borrowings under such debt agreements to be immediately due and payable and, through cross default provisions, would entitle the Company's other lenders to accelerate their loans. At September 30, 2023, the Company was in compliance with these covenants.

The Company expects on an ongoing basis to be able to finance operating cash requirements, capital expenditures, and debt service from the current cash, cash equivalents, cash flows from operations and amounts available under its existing borrowing facilities. The Company's credit facilities are further discussed in Note 12, Financing Arrangements, to the Unaudited Consolidated Financial Statements of this Form 10-Q.

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operating activities and future foreign investments. The Company has the ability to repatriate cash to the United States, which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At September 30, 2023, management believed that sufficient liquidity was available in the United States and expects this to remain for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations, however, these particular repatriation activities have not and are not expected to result in a significant incremental tax liability to the Company.

The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near-term based on strategic capital management. The Company believes there is sufficient liquidity available for the next twelve months.

Material Trends in Capital Resources

On February 14, 2023, the Board of Directors of the Company approved a plan to restructure the Company’s business to improve operational performance and drive shareholder value creation. The plan includes a restructuring of the business through a new operating model with five global business units, optimization of central functions and overall management infrastructure, and other efforts aimed at cost savings. The restructuring plan anticipates a reduction in the Company’s global workforce of approximately 8% to 10%, subject to co-determination processes with employee representative groups in countries where required. The plan is expected to be substantially completed by mid-2024 and result in $200 to $225 million in annual cost savings. Some of the reduction in headcount related to this plan is expected to be offset as the Company makes additional investments including sales personnel and other customer-facing roles.

As of September 30, 2023, in conjunction with this plan the Company has incurred $65 million in restructuring charges primarily related to employee transition, severance payments, employee benefits, and facility closure costs and $14 million in other non-recurring costs related to the restructuring activity which mostly consist of consulting, legal and other professional service fees. The Company expects to incur between $115 to $135 million in one-time charges, comprising of $80 to $100 million in restructuring expenditures and charges, and $35 million in other non-recurring charges, the majority of which are expected to be incurred as cash expenditures in 2023. The estimates of these charges and their timing are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur other charges or cash expenditures in connection with this plan which are not currently contemplated. For further details refer to Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Beginning in the second quarter of 2022, the Company's financial results have also been impacted by the costs associated with the internal investigation conducted and completed by the Audit and Finance Committee and subsequently, the external investigation by the SEC which is currently in progress. These costs have included legal expenses as well as third party accounting and other professional service fees in conjunction with the investigations and subsequent remediation activities still underway. Additionally, the Company has incurred severance costs associated with its remedial personnel actions, as well as special one-time costs in connection with retention of key personnel. These costs totaled approximately $61 million for the year ended December 31, 2022, with additional costs of $14 million incurred in the nine months ended September 30, 2023. The costs in 2023 were offset by a $17 million gain from release of employee compensation accruals resulting from a settlement in the three months ended September 30, 2023. Costs related to remediation activities described in Part I, Item 4 Controls and Procedures of this Form 10-Q are expected to continue further into 2023, and the Company will continue to incur legal defense costs into 2024 pertaining to the matters described in Note 14, Commitments and Contingencies in the Notes to the Unaudited Consolidated Financial Statements.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Part I, Item 1, Note 1, Business and Basis of Presentation, to the Unaudited Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.

Market risk

As filed, 719 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As described in Part I, Item 1, Note 9, Financial Instruments and Derivatives to the Unaudited Consolidated Financial Statements, the Company entered into Swiss franc foreign exchange contracts designated as a net investment hedge. Partly as a result of this activity, at September 30, 2023 a 10% weakening of the U.S. dollar against all other currencies would decrease the net fair value associated with the Company's forward foreign exchange contracts by approximately $99 million. There have been no other material changes from the information provided in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K filed on March 1, 2023 (the "2022 Form 10-K").

Controls and procedures

As filed, 11,087 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company has established disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

The Company's management, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of September 30, 2023, the end of the period covered by this report, and concluded the Company’s disclosure controls and procedures are not effective due to the material weaknesses in internal control over financial reporting as described below under “Material Weaknesses in Internal Control over Financial Reporting."

Material Weaknesses in Internal Control over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

As described in the Explanatory Note to the Form 10-K for the year ended December 31, 2021, as amended and filed on November 7, 2022, management identified the following material weaknesses in the Company's internal control over financial reporting, which continue to exist as of September 30, 2023:

a. The Company did not design and maintain an effective internal control environment, as former management failed to set an appropriate tone at the top. Specifically, certain members of senior management, including the Company’s former Chief Executive Officer and former Chief Financial Officer, engaged in conduct that was inconsistent with the Company’s culture of compliance and Code of Ethics and Business Conduct.

b. The Company did not maintain a sufficient complement of personnel with an appropriate level of knowledge about accounting for variable consideration related to customer incentive arrangements in a manner commensurate with our financial reporting requirements.

These material weaknesses contributed to the following additional material weakness:

c. The Company did not design and maintain effective controls associated with approving, communicating, and accounting for incentive arrangements with customers, impacting the completeness and accuracy of revenues, including variable consideration.

As previously disclosed in the Company's Current Report on Form 8-K filed August 2, 2023, subsequent to the filing of the Company's Quarterly Report on Form 10-Q filed May 3, 2023, management identified the following additional material weakness in the Company’s internal control over financial reporting, which continues to exist as of September 30, 2023:

d. The Company did not design and maintain effective controls relating to the segregation of duties specific to the creation of manual journal entries.

Each of these material weaknesses could result in a misstatement of substantially all of our account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

As of the filing of this Form 10-Q, the material weaknesses described above have not been remediated. The material weaknesses described above cannot be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. Based on the implementation of these remedial actions, we will continue to monitor and test controls for effectiveness through the end of the observation period. Accordingly, management will continue to monitor and evaluate the effectiveness of our internal control over financial reporting in the activities affected by the material weaknesses described above.

Remediation Plan and Status

While the material weaknesses previously disclosed have not yet been remediated as of September 30, 2023, management has devoted substantial resources to the implementation of remediation efforts to address the material weaknesses described herein, as well as other identified areas of risk. These efforts, summarized below, which have been implemented and are currently being tested for their effectiveness in remediating the identified material weaknesses, are also intended to enhance the Company’s overall internal control over financial reporting and disclosure controls and procedures.

With oversight from the Audit and Finance Committee and input from the Board of Directors, management has enhanced and implemented changes in processes, systems, and controls intended to remediate the material weaknesses described in the Material Weaknesses in Internal Control over Financial Reporting section above and to improve our internal control over financial reporting as noted below. Management and the Board of Directors, including the Audit and Finance Committee, are working to remediate the material weaknesses identified herein. Actions taken to date include:

a. Appointment of a new Chief Executive Officer, a new Chief Financial Officer and a new Chief Accounting Officer;

b. Termination of certain members of senior management as well as non-executive employees for violations of the Code of Ethics and Business Conduct;

c. Reviewed and enhanced the Company's Code of Ethics and Business Conduct including to clarify responsibilities related to the Company's financial reporting and disclosures;

d. Implemented general training programs on revenue recognition for commercial and finance personnel;

e. Established requirements and provided trainings for employees who have a role in negotiating, assessing, agreeing, and accounting for customer incentive arrangements with distributors;

f. Implemented commercial contracting policies and provided training on new processes to individuals responsible for execution, oversight and review of customer incentive arrangements with customers;

g. Implemented written policies and procedures to provide governance and establish responsibility for oversight of incentive arrangements provided to customers in North America, including the appropriate delegation of authority for such approvals;

h. Provided incremental training to Company personnel on the updated Code of Ethics and Business Conduct;

i. Implemented written policies and procedures to require review and approval of and establish oversight responsibility over incentive arrangements provided to customers in China, including the appropriate delegation of authority for such approvals;

j. Formalized written policies and procedures to provide governance and establish responsibility for guidelines, documentation and oversight of product returns from customers when a contractual right to return exists in a customer agreement;

k. Enhanced processes to ensure all applicable terms and conditions for incentive-based programs and customer agreements are timely communicated to individuals responsible for accounting and financial reporting;

l. Strengthened internal controls over the accounting for customer incentive arrangements, including implementing: (i) formal controls to continuously review and document the methodology and assumptions used in estimating variable based incentives and (ii) formal controls to ensure the accuracy of the estimated accrued liability analysis;

m. Evaluated finance and commercial operations talent and address identified gaps; and

n. Established a recurring cadence for future training programs on revenue recognition for commercial and finance personnel.

In addition, the Company took the following remedial actions to improve disclosure controls and procedures:

a. Enhanced existing Disclosure Committee responsibilities through adoption of a formal charter, which identifies members and sets forth the roles and responsibilities of the Disclosure Committee, among other requirements; and

b. Implemented additional and enhanced existing sub-certifications and internal management representation letters, including providing training on the purpose of the sub-certification and the process for evaluating the representations.

In connection with the material weakness relating to segregation of duties specific to the creation of manual journal entries, the Company took the following remedial actions:

a. Implemented further segregation of duties in the performance of controls around manual journal entries, including implementing restrictions to user access rights in our general ledger systems to post manual journal entries, to ensure that reviewers of manual journal entries do not also have the ability to create and post such entries;

b. Modified existing processes to enhance use of approval workflows in our process to document, support and review manual journal entries; and

c. Enhanced the global policy on manual journal entries, including appropriate entry approval authorization and training of requisite personnel.

Under the direction of the Audit and Finance Committee, Management has overseen the planning and effective execution of the remediation efforts described above. Management believes the foregoing efforts have effectively addressed the material weaknesses described above; however, more time is needed for the improved controls to operate and undergo testing of effectiveness before they can be deemed remediated. As the Company continues to evaluate and improve its internal control over financial reporting and disclosure controls and procedures, management may determine to take additional measures to improve controls or determine to modify the remediation plan described above. Procedures to implement and evaluate this remediation plan have to date required significant amounts of time, allocation of internal resources and external costs, and remaining remediation activities of testing and demonstrating operating effectiveness of these controls will continue to place significant demands on financial and operational resources until these remaining efforts are completed.

Changes in Internal Control Over Financial Reporting

Except for progress made on the remediation activities described in the Remediation Plan and Status section above, there have been no changes in the Company’s internal control over financial reporting that occurred during the three months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

Risk factors

As filed, 11,513 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We have updated two risk factors as disclosed in Part I, Item 1A, “Risk Factors” in the 2022 Form 10-K, as amended, as follows:

We have recognized substantial goodwill and indefinite-lived intangible asset impairment charges, most recently in the September 2023 quarter, and may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future.

We review amortizable intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. We test goodwill and indefinite-lived intangibles for impairment at least annually. The valuation models used to determine the fair value of goodwill or indefinite-lived intangible assets are dependent upon various assumptions and reflect management's best estimates. We have acquired other companies and intangible assets and may not realize all the economic benefit from those acquisitions, which could cause an impairment of goodwill or intangibles.

The goodwill and indefinite-lived intangible asset impairment analyses are sensitive to changes in key assumptions used, such as discount rates, revenue growth rates, perpetual revenue growth rates, operating margin percentages, and net working capital assumptions of the business as well as current market conditions affecting the dental and medical device industries in both the U.S. and globally. Given the uncertainty in the marketplace and other factors affecting management's assumptions underlying our discounted cash flow model, the assumptions and projections used in the analyses may not be realized and our current estimates could vary significantly in the future, which may result in an additional goodwill or indefinite-lived intangible asset impairment charge at that time.

In the quarter ended September 30, 2023, the Company identified indicators of a "more likely than not" impairment related to its Connected Technology Solutions reporting unit, which comprises all of the Connected Technology Solutions segment. As a result, the Company recorded a pre-tax goodwill impairment charge as of September 30, 2023 related to the Connected Technology Solutions reporting unit of $291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment.

Additionally, in conjunction with the goodwill impairment test in the quarter ended September 30, 2023, the Company tested the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment for impairment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment, and determined certain tradenames and trademarks were impaired. As a result, the Company recorded indefinite-lived intangible asset impairment charges of $14 million and $2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2023, any further decline in key assumptions could result in additional impairment in future periods. At September 30, 2023, the Company has $431 million of indefinite-lived intangible assets and $2.4 billion of goodwill recorded on its balance sheet.

For the three months ended September 30, 2023, the Company considered qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in the likelihood that the goodwill or indefinite-lived intangible assets may have become more likely than not impaired during the course of the quarter. For the reporting units and indefinite-lived intangible assets for which no triggering event was identified, the Company performed a hypothetical sensitivity analysis by increasing the discount rate by 100 basis points. If discount rates were hypothetically increased by 100 basis points at September 30, 2023, the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was $1,133 million at September 30, 2023. Additionally under this sensitivity, certain indefinite-lived intangibles within the Connected Technology Solutions and Essential Dental Solutions segments would have a fair value less than 10% in excess of carrying value. The carrying value of these indefinite-lived intangible assets within the aforementioned segments was $27 million and $7 million, respectively, at September 30, 2023. Refer to Part I, Item 1, Note 13, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements for further discussion of the Company's goodwill and indefinite-lived intangible asset impairment testing.

Due to the international nature of our business, including increasing exposure to markets outside of the U.S., political or economic changes or other factors could harm our business and financial performance.

Approximately two-thirds of our sales are located in regions outside the U.S. In addition, we anticipate that sales outside of the U.S. will continue to expand and account for a significant portion of our revenue. Operating internationally is subject to a number of uncertainties, including, but not limited to, the following:

  • economic and political instability;
  • import or export licensing requirements;
  • additional compliance-related risks;
  • trade restrictions and tariffs;
  • product registration requirements;
  • longer payment cycles;
  • changes in regulatory requirements and tariffs, including recent restrictions in China on the proportion of certain medical equipment which can be imported;
  • potentially adverse tax consequences; and
  • trade policy changes

Changes in or the imposition of tariffs could make it more difficult or costly for us to export our products to other countries. These measures could also result in increased costs for goods imported into the U.S. This in turn could require us to increase prices to our customers which may reduce demand, or, if we are unable to increase prices, result in lowering our margin on products sold. We cannot predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business. The adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies has the potential to adversely impact demand for our products, our costs, our customers and our suppliers, which in turn could adversely impact our business, financial condition and results of operations.

Certain of these risks may be heightened as a result of changing political climates which may lead to changes in areas such as trade restrictions and tariffs, regulatory requirements and exchange rate fluctuations, which may adversely affect our business and financial performance. For example, as a result of escalating tensions and the subsequent invasion of Ukraine by Russia, the U.S., other North Atlantic Treaty Organization member states, the EU and other countries have imposed sanctions on Russia, including its major financial institutions and certain other businesses and individuals, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People’s Republic and the so-called Luhansk People’s Republic. Russia also imposed significant currency control measures aimed at restricting the outflow of foreign currency and capital from Russia, imposed various restrictions on transacting with non-Russian parties, banned exports of various products, and imposed other economic and financial restrictions. These include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia. Russia may further respond in kind, and the continuation of the conflict may result in additional sanctions being enacted by the U.S., other North Atlantic Treaty Organization member states, the EU or other countries. The length, impact, and outcome of this ongoing military conflict is highly unpredictable and could lead to significant market and other disruptions, which, along with the spillover effect of ongoing civil, political and economic disturbances on surrounding areas, may significantly devalue currencies utilized by us or have other adverse impacts including increased costs of raw materials and inputs, manufacturing or shipping delays or increases in inflation rate, cyber attacks and supply chain challenges. Export controls implemented as part of sanctions could also restrict the sale of equipment or products containing U.S. developed software and technology into Russia.

For the quarter ended September 30, 2023, net sales in Russia and Ukraine were approximately 2% of our consolidated net sales, and net assets in these countries were $57 million. These net assets include $34 million of cash and cash equivalents held within Russia as of September 30, 2023. Due to currency control measures imposed by the Russian government which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we may be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs, if at all.

The recent terrorist attacks by Hamas militants crossing the border from Gaza to Israel in October 2023 and the subsequent military response by the Israeli government has resulted in significant unrest and uncertainty within that region, including the possibility that escalating violence and involvement of other terrorist groups from neighboring countries may further impact our employees and operations. The Company’s operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one in southern Israel, and employs approximately 315 associates. These facilities remain open and continue to operate. We may, however, determine to discontinue production for the safety of our employees, or we could face future production slowdowns or interruptions at either location due to the impacts of the war including personnel absences as a number of our employees have been called to active military duty, or due to other resource constraints such as the inability to source materials for production. For the quarter ended September 30, 2023, net sales of products manufactured at these sites comprise approximately 3% of our consolidated net sales and 18% of the net sales attributed to our Orthodontics and Implants Solutions segment. Net assets within Israel total $193 million as of September 30, 2023, consisting primarily of acquired technology, cash, inventory, and property, plant and equipment associated our operations in country.

The full impact of these events on economic conditions in these regions is currently unknown and could have a material adverse effect on our results of operations, cash flows or financial condition.

There have been no other material changes to the risk factors as previously disclosed in the 2022 Form 10-K, as amended.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-01 to 2023-09-30$947.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2023-01-01 to 2023-09-30$2.95bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-07-01 to 2023-09-30$452.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2023-01-01 to 2023-09-30$1.39bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-07-01 to 2023-09-30$495.0mus-gaap:GrossProfit
Gross profit9 months2023-01-01 to 2023-09-30$1.56bnus-gaap:GrossProfit
Research and development3 months2023-07-01 to 2023-09-30$46.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2023-01-01 to 2023-09-30$141.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2023-07-01 to 2023-09-30$372.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2023-01-01 to 2023-09-30$1.20bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-07-01 to 2023-09-30−$236.0mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30−$158.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-07-01 to 2023-09-30$18.0mus-gaap:InterestExpense
Interest expense9 months2023-01-01 to 2023-09-30$58.0mus-gaap:InterestExpense
Income tax3 months2023-07-01 to 2023-09-30$16.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30−$28.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30−$266.0mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30−$199.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30−$1.25us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30−$0.94us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30−$1.25us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30−$0.94us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-30211,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-30212,700,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30$217.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$109.0mus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid9 months2023-01-01 to 2023-09-30$86.0mus-gaap:PaymentsOfDividends
Share repurchases9 months2023-01-01 to 2023-09-30$150.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-09-30$309.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$1.91bnus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$7.20bnus-gaap:Assets
Current liabilitiesAt period end2023-09-30$1.22bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$3.83bnus-gaap:Liabilities
Long-term debtAt period end2023-09-30$1.80bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2023-09-30$187.0mus-gaap:DebtCurrent
Shareholders' equityAt period end2023-09-30$3.38bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000818479-23-000084. Last ingested by Listed: Nov 14, 2026, 19:27 ET. Listed shows no prices and gives no investment advice.